Skip to main content

Rubius Therapeutics, Inc.

RUBYDelisted Mar 28, 2023
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001709401

Rubius Therapeutics, Inc. was delisted on Mar 28, 2023; its insiders filed their last Form 4 on Feb 27, 2023; 42 institutions reported holding it in 13F filings for Q4 2022, worth $11.2M in total; no superinvestor held it.

13F holders, Q1 2021

Institutional positions in Rubius Therapeutics, Inc. as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
105
No complete 13F data for Q4 2020
Shares held
84.0M
No complete 13F data for Q4 2020
Total value
$2.23B
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting RUBY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 105 institutions
Q1 2021: 105 institutionsQ2 2021: 108 institutionsQ3 2021: 105 institutionsQ4 2021: 108 institutionsQ1 2022: 117 institutionsQ2 2022: 73 institutionsQ3 2022: 62 institutionsQ4 2022: 42 institutionsQ1 2023: 7 institutionsQ2 2023: 0 institutionsQ3 2023: 0 institutionsQ4 2023: 0 institutionsQ1 2024: 0 institutionsQ2 2024: 0 institutionsQ3 2024: 0 institutionsQ4 2024: 0 institutionsQ1 2025: 0 institutionsQ2 2025: 0 institutionsQ3 2025: 0 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ1 2021: $2.23B
Q1 2021: $2.23BQ2 2021: $2.09BQ3 2021: $1.55BQ4 2021: $863.6MQ1 2022: $493.9MQ2 2022: $66.6MQ3 2022: $29.7MQ4 2022: $11.2MQ1 2023: $61.3KQ2 2023: $0Q3 2023: $0Q4 2023: $0Q1 2024: $0Q2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding RUBY and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 20250$0
Q2 20250$0
Q1 20250$0
Q4 20240$0
Q3 20240$0
Q2 20240$0
Q1 20240$0
Q4 20230$0
Q3 20230$0
Q2 20230$0
Q1 20237$61.3K
Q4 202242$11.2M
Q3 202262$29.7M
Q2 202273$66.6M
Q1 2022117$493.9M
Q4 2021108$863.6M
Q3 2021105$1.55B
Q2 2021108$2.09B
Q1 2021105$2.23B

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding Rubius Therapeutics, Inc..

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding RUBY in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock Inc.3,637,617$96.4M0.00%––
Baillie Gifford & Co4,693,871$124.4M0.07%––
Artal Group S.A.4,883,791$129.4M2.74%––
FMR LLC13,527,493$358.5M0.03%––
Flagship Pioneering Inc.38,506,526$1.02B16.34%––